Quarterly ResultAug 5, 2026, 04:04 PM
Revolution Medicines: FDA Accepts Daraxonrasib NDA; Breakthrough Status
AI Summary
Revolution Medicines announced its Q2 2026 financial results and significant corporate progress. The U.S. FDA accepted the New Drug Application for daraxonrasib for metastatic pancreatic cancer and granted Breakthrough Therapy Designation for daraxonrasib in RAS mutant non-small cell lung cancer. The company also achieved U.S. commercial launch readiness and reported encouraging clinical data for elironrasib and zoldonrasib in NSCLC. While R&D and G&A expenses increased, leading to a higher net loss, the company maintains a strong cash position of $3.9 billion.
Key Highlights
- FDA accepted daraxonrasib NDA for previously treated metastatic pancreatic cancer.
- FDA granted Breakthrough Therapy Designation for daraxonrasib in RAS mutant NSCLC.
- Achieved U.S. commercial launch readiness for daraxonrasib.
- Daraxonrasib distributed to over 2,000 patients via Expanded Access Program.
- Q2 2026 R&D expenses increased to $394.9 million from $224.1 million YoY.
- Q2 2026 G&A expenses increased to $110.2 million from $40.6 million YoY.
- Q2 2026 Net Loss was $644.4 million, up from $247.8 million YoY.
- Cash, cash equivalents, and marketable securities totaled $3.9 billion.
Price Impact
More from RVMD